Investigator Perspectives

Hatim Husain, MD, discusses how recent updates on acquired resistance mechanisms and overall survival data for combination therapies involving amivantamab, lazertinib, and chemotherapy in EGFR-mutated NSCLC patients progressing after first-line osimertinib treatment are shaping the evolving treatment landscape and influencing clinical decision-making.

Saeed Sadeghi, MD, discusses a case of lower-risk myelodysplastic syndromes (LR-MDS), focusing on the mechanisms of action for luspatercept vs epoetin alfa, insights from the COMMANDS study, real-world data on treatment outcomes, health care resource utilization, and future directions in anemia management within this patient population.

Yoshiaki Nakamura, MD, PhD, discusses how a methylation-based circulating tumor DNA assay can enhance minimal residual disease detection and improve prognosis in patients with previously treated stage II-III colorectal cancer.

Rana McKay, MD, discusses how the first-line treatment landscape for metastatic renal cell carcinoma has evolved, comparing efficacy and safety profiles of various treatment combinations, considering patient-specific factors and disease characteristics in treatment selection, addressing the management of adverse events, and exploring ongoing challenges and future directions in therapy.

Following EHA 2024, Mazyar Shadman, MD, MPH, discusses recent updates in the evolving treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Guillermo Garcia-Manero, MD, discusses recent updates surrounding the role of erythroid maturation agents for treating anemia in patients with lower-risk myelodysplastic syndromes.

Martin H. Voss, MD, discusses recent advances in the treatment of advanced non–clear cell renal cell carcinoma and their impact on clinical practice.

Dr Dhakal provided an overview of the clinical hallmarks and risk stratification for R/R MM, as well as the current standard of care treatment options. He explored the role of CAR T-cell therapy in this setting, including an overview of the CAR-T process and criteria for identifying suitable patients.

Expert Dr. Elizabeth Plimack discusses the evolving treatment landscape of non-clear cell RCC.

Gary J. Schiller, MD, a hematologist/oncologist from UCLA Health Jonsson Comprehensive Cancer Center, provides expert perspectives on recent data updates presented at the 2023 ASH Annual Meeting.

Guillermo Garcia-Manero, MD, discusses recent advances presented at ASH 2023 in the treatment of myelodysplastic syndrome, highlighting both safety and efficacy of regimens in the frontline and second line setting.

Expert oncologists discuss the evolving treatment landscape in ER+/HER2- Metastatic Breast Cancer.

Siamak Daneshmand, MD, provides an overview of BCG-unresponsive non-muscle invasive bladder cancer and the currently available treatment options; Dr Daneshmand explains that new intravesical therapies like the TAR-200 device show promise but still require vigilant monitoring to avoid delaying cystectomy, which remains the best chance for long-term management.

Abdulraheem Yacoub, MD, discusses the diagnosis and prognostic scoring of patients with myelofibrosis and reviews the best treatment approaches including JAK inhibitors and management of severe anemia.

Rebecca A. Shatsky, MD, a medical oncologist, provides clinical insights on biomarker testing paradigms for patients with ER+/HER2- metastatic breast cancer.

Matthew A. Powell, MD, reviews recent advances in the treatment of patients with endometrial carcinoma, referencing several key clinical trials and real-world datasets.

Robert J. Motzer, MD, an expert on renal cell carcinoma, reviews recent data updates from clinical trials and offers insights on the evolving treatment landscape.

Expert oncologist discusses clinical trial insights and the evolving treatment landscape in advanced renal cell carcinoma to optimize patient outcomes and quality of life.

Amer Zeidan, MBBS, reviews data from the phase 3 COMMANDS trial investigating the first-line treatment of anemia associated with lower-risk myelodysplastic syndromes.

Aaron Gerds, MD, MS, provides an overview of myelofibrosis and its changing treatment landscape.

Expert hematologist Stephen Oh, MD, PhD, provides an overview of myelofibrosis, and discusses how new data from ASH 2022 affect the treatment landscape.

Lori Wirth, MD, provides an overview of radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC), the standard-of-care treatment options, and the importance of testing for molecular alterations in patients with RAI-R-DTC.

Rana McKay, MD discusses emerging data in the metastatic renal cell carcinoma treatment landscape, reviewing the current standard of care and then delving into recent data updates from the CheckMate 9ER and COSMIC-313 trials.

Lori Wirth, MD, reviews real-world and clinical trial data on treatment of advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC) with lenvatinib, and her personal experience with lenvatinib in clinical practice.

Edward B. Garon, MD, MS, provides his expert perspective on immune checkpoint inhibition in metastatic non-small cell lung cancer (mNSCLC) and evaluates the currently available immunotherapy combinations.

Dr Aditya Bardia reviews the potential role of elacestrant for the treatment of metastatic ER+/HER2- breast cancer, starting with an overview of the current landscape and focusing specifically on key efficacy data from the EMERALD Trial.

Naveen Pemmaraju, MD, explains the types of myeloproliferative neoplasms, the currently available treatment options, and how treatment approaches have changed historically.

Robert Zeiser, MD, discusses the landscape of graft versus host disease and reviews data related to the current treatment options.